<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23178532</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>187</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of virological methods</Title><ISOAbbreviation>J Virol Methods</ISOAbbreviation></Journal><ArticleTitle>Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum.</ArticleTitle><Pagination><StartPage>362</StartPage><EndPage>367</EndPage><MedlinePgn>362-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jviromet.2012.11.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-0934(12)00394-1</ELocationID><Abstract><AbstractText>Serum neutralizing antibody titers are indicative of protective immunity against Coxsackievirus A16 (CV-A16) and Enterovirus 71 (EV71), the two main etiological agents of hand, foot and mouth disease (HFMD), and provide the basis for evaluating vaccine efficacy. The current CV-A16 neutralization assay based on inhibition of cytopathic effects requires manual microscopic examination, which is time-consuming and labor-intensive. In this study, a high-throughput neutralization assay was developed by employing CV-A16 pseudoviruses expressing luciferase for detecting infectivity in rhabdomyosarcoma (RD) cells and measuring serum viral neutralizing antibodies. Without the need to use infectious CV-A16 strains, the neutralizing antibody titer against CV-A16 could be determined within 15h by measuring luciferase signals by this assay. The pseudovirus CV-A16 neutralization assay (pCNA) was validated by comparison with a conventional CV-A16 neutralization assay (cCNA) in testing 174 human serum samples collected from children (age &lt;5 years). The neutralizing antibody titers determined by these two assays were well correlated (R(2)=0.7689). These results suggest that the pCNA can serve as a rapid and objective procedure for the measurement of neutralizing antibodies against CV-A16.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Life Science, Jilin University, Changchun 130012, China. jinjunjlu@126.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Hongxia</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Shiyang</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xueyong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chunlai</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Virol Methods</MedlineTA><NlmUniqueID>8005839</NlmUniqueID><ISSNLinking>0166-0934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="Y">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019411" MajorTopicYN="N">Clinical Laboratory Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044967" MajorTopicYN="N">Serum</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23178532</ArticleId><ArticleId IdType="pmc">PMC7112850</ArticleId><ArticleId IdType="doi">10.1016/j.jviromet.2012.11.014</ArticleId><ArticleId IdType="pii">S0166-0934(12)00394-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ang L.W., Koh B.K., Chan K.P., Chua L.T., James L., Goh K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001&#x2013;2007. Ann. Acad. Med. Singapore. 2009;38:106&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">19271036</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Ami Y., Wakita T., Shimizu H. Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol. 2008;82:1787&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258712</ArticleId><ArticleId IdType="pubmed">18057246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartosch B., Bukh J., Meunier J.C., Granier C., Engle R.E., Blackwelder W.C., Emerson S.U., Cosset F.L., Purcell R.H. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. U.S.A. 2003;100:14199&#x2013;14204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283569</ArticleId><ArticleId IdType="pubmed">14617769</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., King C.C., Hsu K.H., Ning H.C., Tsao K.C., Li C.C., Huang Y.C., Shih S.R., Chiou S.T., Chen P.Y., Chang H.J., Lin T.Y. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002;109:e88.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., Lin T.Y., Huang Y.C., Tsao K.C., Shih S.R., Kuo M.L., Ning H.C., Chung P.W., Kang C.M. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr. Infect. Dis. J. 1999;18:1092&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Mou X., Zhang Q., Li Y., Lin J., Liu F., Yuan L., Tang Y., Xiang C. Detection of human enterovirus 71 and coxsackievirus A16 in children with hand, foot and mouth disease in China. Mol. Med. Rep. 2012;5:1001&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493055</ArticleId><ArticleId IdType="pubmed">22218731</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper D.J., Shaw D.R., LaBrooy J.T., Blumbergs P., Gilbert J., Simmons A. Fatal rhabdomyolysis and renal failure associated with hand, foot and mouth disease. Med. J. Aust. 1989;151:232&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">2548069</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushi S., Mizutani T., Saijo M., Kurane I., Taguchi F., Tashiro M., Morikawa S. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J. Med. Virol. 2006;78:1509&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166816</ArticleId><ArticleId IdType="pubmed">17063504</ArticleId></ArticleIdList></Reference><Reference><Citation>Horodniceanu F., Panon G., Le Fur R., Barme M. Purification of poliovirus obtained from human diploid cells by means of DEAE-Sepharose. Dev. Biol. Stand. 1979;42:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">223925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya M., Kawasaki Y., Sato M., Honzumi K., Hayashi A., Hiroshima T., Ishiko H., Kato K., Suzuki H. Genetic diversity of coxsackievirus A16 associated with hand, foot, and mouth disease epidemics in Japan from 1983 to 2003. J. Clin. Microbiol. 2007;45:112&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1828949</ArticleId><ArticleId IdType="pubmed">17093028</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck Z.Y., Li T.K., Xia J., Bartosch B., Cosset F.L., Dubuisson J., Foung S.K. Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J. Virol. 2005;79:13199&#x2013;13208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1262592</ArticleId><ArticleId IdType="pubmed">16227243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobinger G.P., Figueredo J.M., Rowe T., Zhi Y., Gao G., Sanmiguel J.C., Bell P., Wivel N.A., Zitzow L.A., Flieder D.B., Hogan R.J., Wilson J.M. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine. 2007;25:5220&#x2013;5231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7115643</ArticleId><ArticleId IdType="pubmed">17559989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung S.H., Wang S.F., Huang C.W., Hsu C.C., Liu H.F., Yang J.Y. Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998&#x2013;2005. Clin. Microbiol. Infect. 2007;13:782&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">17488328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T.C., Guo H.R., Su H.J., Yang Y.C., Chang H.L., Chen K.T. Diseases caused by enterovirus 71 infection. Pediatr. Infect. Dis. J. 2009;28:904&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">20118685</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., He Y., Yang H., Zhu J., Xu X., Dong J., Zhu Y., Jin Q. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J. Clin. Microbiol. 2005;43:3835&#x2013;3839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1233905</ArticleId><ArticleId IdType="pubmed">16081920</ArticleId></ArticleIdList></Reference><Reference><Citation>Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 2005 12.11.1&#x2013;12.11.17.</Citation><ArticleIdList><ArticleId IdType="pubmed">18432938</ArticleId></ArticleIdList></Reference><Reference><Citation>Motulsky H., Christopoulos A. Oxford University Press; New York: 2004. Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting.</Citation></Reference><Reference><Citation>Netski D.M., Mosbruger T., Depla E., Maertens G., Ray S.C., Hamilton R.G., Roundtree S., Thomas D.L., McKeating J., Cox A. Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis. 2005;41:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">16080089</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera D., Yusof M.A., Podin Y., Ooi M.H., Thao N.T., Wong K.K., Zaki A., Chua K.B., Malik Y.A., Tu P.V., Tien N.T., Puthavathana P., McMinn P.C., Cardosa M.J. Molecular phylogeny of modern coxsackievirus A16. Arch. Virol. 2007;152:1201&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308978</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabenau H.F., Richter M., Doerr H.W. Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med. Microbiol. Immunol. 2010;199:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">19941005</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938;27:493&#x2013;497.</Citation></Reference><Reference><Citation>Solomon, Lewthwaite T., Perera P., Cardosa D., McMinn M.J., Ooi P., Virology M.H. Epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamin A., Harcourt B.H., Lo M.K., Roth J.A., Wolf M.C., Lee B., Weingartl H., Audonnet J.C., Bellini W.J., Rota P.A. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods. 2009;160:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704486</ArticleId><ArticleId IdType="pubmed">19559943</ArticleId></ArticleIdList></Reference><Reference><Citation>Temperton N.J., Chan P.K., Simmons G., Zambon M.C., Tedder R.S., Takeuchi Y., Weiss R.A. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 2005;11:411&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298259</ArticleId><ArticleId IdType="pubmed">15757556</ArticleId></ArticleIdList></Reference><Reference><Citation>Troupin C., Dehee A., Schnuriger A., Vende P., Poncet D., Garbarg-Chenon A. Rearranged genomic RNA segments offer a new approach to the reverse genetics of rotaviruses. J. Virol. 2010;84:6711&#x2013;6719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903292</ArticleId><ArticleId IdType="pubmed">20427539</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.Y., Li Lu F., Wu M.H., Lee C.Y., Huang L.M. Fatal coxsackievirus A16 infection. Pediatr. Infect. Dis. J. 2004;23:275&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">15014311</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Butler E.N., Veguilla V., Vassell R., Thomas J.T., Moos M., Jr., Ye Z., Hancock K., Weiss C.D. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods. 2008;153:111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">18722473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S.S., Yip C.C., Lau S.K., Yuen K.Y. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol. Infect. 2010;138:1071&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">20056019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright E., Temperton N.J., Marston D.A., McElhinney L.M., Fooks A.R., Weiss R.A. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J. Gen. Virol. 2008;89:2204&#x2013;2213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886951</ArticleId><ArticleId IdType="pubmed">18753230</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip C.C., Lau S.K., Zhou B., Zhang M.X., Tsoi H.W., Chan K.H., Chen X.C., Woo P.C., Yuen K.Y. Emergence of enterovirus 71 double-recombinant strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch. Virol. 2010;155:1413&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087135</ArticleId><ArticleId IdType="pubmed">20549263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H.M., Li C.R., Liu Y.J., Liu W.L., Fu D., Xu L.M., Xie J.J., Tan Y., Wang H., Chen X.C., Zhou B.P. To investigate pathogen of hand, foot and mouth disease in Shenzhen in 2008. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2009;23:334&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">20387478</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhu Z., Yang W., Ren J., Tan X., Wang Y., Mao N., Xu S., Zhu S., Cui A., Yan D., Li Q., Dong X., Zhang J., Zhao Y., Wan J., Feng Z., Sun J., Wang S., Li D., Xu W. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol. J. 2010;7:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Kong F., Wang B., McPhie K., Gilbert G.L., Dwyer D.E. Molecular characterization of enterovirus 71 and coxsackievirus A16 using the 5&#x2032; untranslated region and VP1 region. J. Med. Microbiol. 2010;60:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">21148280</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>